Press release | 5th January 2011
Lonza Selects IDBS to Optimize Bioprocess Execution & Knowledge Management
Basel, Switzerland, and Guildford, United Kingdom, 5 January 2011 – Lonza has chosen IDBS, a leading global provider of data management and analytics solutions to R&D organizations, to provide an electronic data management and execution solution for mammalian cell culture process development. Lonza, a world leader in biopharmaceutical development and production, will deploy IDBS’s Bioprocess Execution System to optimize the management of process development data and drive operational excellence to Lonza customers.
“We believe that adopting IDBS’s Bioprocess Execution System as our data management solution will help us improve our processes and enhance the quality of the services we provide to customers,”
said Dr. Steve Flatman, Head of Mammalian Development Services.
“After due consideration the IDBS software and service offering was our preferred solution. The knowledge and expertise of IDBS staff in the bioscience arena was a key factor in our decision.”
Due to the complex nature of biopharmaceutical processes, pharmaceutical companies invest considerable time and money generating high-value data throughout the development lifecycle. This information is often locked in paper records or isolated electronic files, across multiple locations and in different formats, making it difficult to manage and analyze process data efficiently. As a result, organizations such as Lonza are turning to data management systems to integrate and optimize bioprocess workflows. This enables management of the complete laboratory-to-report lifecycle within one system, and makes data retrievable by scientists to help in targeting process optimizations. This, in turn, will assist the drive for operational excellence, a core part of Lonza’s strategy.
“IDBS continues to develop informatics solutions that address the critical business needs of high value R&D and manufacturing activities,”
said Neil Kipling, founder and CEO of IDBS.
“We believe that the bioprocess sector is an area of considerable growth and will benefit from our broad expertise and industry experience. We are delighted to be working with such an innovative company as Lonza, one of the first contract manufacturers to adopt our approach to process and knowledge management.”
About the Bioprocess Execution System
The Bioprocess Execution System – which is based upon IDBS’ data management technology – is a framework that enables organizations to streamline unit operations and optimize bioprocess workflows, from development to production, while maintaining the highest levels of quality and process insight.
The Bioprocess Execution System allows data to be stored in context and more effectively shared between groups, deployed as a source of corporate knowledge, and used to monitor and improve process development and biological production operations.
Lonza is one of the world’s leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2009, the company had sales of CHF 2.690 billion. Further information can be found at www.lonza.com.
IDBS is a unique, global supplier of innovative data management and first-in-class analytics solutions which increase efficiency reduce costs and improve the productivity of healthcare R&D organizations. Multinational pharmaceutical companies, major public-private healthcare partnerships, global leaders in academic study and high tech companies employ IDBS as a strategic supplier of scientific informatics and business process improvement solutions. IDBS is clearly differentiated by its unique combination of deep domain knowledge across the entire R&D sector: from the examination of the human genome at the scientist’s bench, through the clinic, to translational medicine initiatives and pay-for-performance healthcare monitoring. IDBS solutions support the protection of intellectual property (IP) and the requirements for data quality and security demanded under Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP) and HL7 (Health Level) standards.
Founded in 1989 and headquartered in Guildford, UK, IDBS has worldwide consulting and support presence, with offices in California, New Jersey and Massachusetts, as well as in the EU, Australia and China. IDBS is a 2010 Profit Track 100 company.